Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Thymectomy, Cholinesterase Inhibitors, Rapid Immunotherapies), By End-use (Hospitals, Clinics), By Region and Segment Forecasts, 2023 - 2030

Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Thymectomy, Cholinesterase Inhibitors, Rapid Immunotherapies), By End-use (Hospitals, Clinics), By Region and Segment Forecasts, 2023 - 2030


Myasthenia Gravis Treatment Market Growth & Trends


The global myasthenia gravis treatment market size is expected to reach USD 4.26 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.0% from 2023 to 2030. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

Myasthenia Gravis Treatment Market Growth & Trends


  • Medications can dramatically inhibit the immune system and largely manage the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine).
  • The monoclonal antibodies segment held the largest market share of over 60% in 2022 and is expected to maintain its leading position through the forecast period, owing to the high precision in treating myasthenia gravis and better efficacy.
  • Based on end use, the market has been segmented into hospitals, clinics, and others. The hospital segment held the largest market share of around 55% in 2022 and is expected to grow at a lucrative CAGR of 9.0% over the forecast period.
  • In 2022, North America had the largest market share of over 50% and is projected to lead the market throughout the forecast period.
  • Asia Pacific is anticipated to grow at a lucrative CAGR through the forecast period due to the increase in revenue generation from medications such as immunosuppressants and monoclonal antibodies in this region.
  • Please note The report will be delivered in 2-3 business days upon order notification.


    Chapter 1. Methodology and Scope
    1.1. Market Segmentation & Scope
    1.1.1. Treatment Type
    1.1.2. End use
    1.1.3. Regional scope
    1.1.4. Estimates and forecast timeline
    1.2. Research Methodology
    1.3. Information Procurement
    1.3.1. Purchased database
    1.3.2. GVR’s internal database
    1.3.3. Secondary sources
    1.3.4. Primary research
    1.3.5. Details of primary research
    1.4. Information or Data Analysis
    1.5. Market Formulation & Validation
    1.6. Model Details
    1.7. List of Secondary Sources
    1.8. List of Primary Sources
    1.9. Objectives
    Chapter 2. Executive Summary
    2.1. Market Outlook
    2.2. Segment Outlook
    2.2.1. Treatment outlook
    2.2.2. End use outlook
    2.2.3. Regional outlook
    2.3. Competitive Insights
    Chapter 3. Myasthenia Gravis Treatment Market Variables, Trends & Scope
    3.1. Market Lineage Outlook
    3.1.1. Parent market outlook
    3.1.2. Related/ancillary market outlook
    3.2. Penetration & Growth Prospect Mapping
    3.3. Market Dynamics
    3.3.1. Market driver analysis
    3.3.2. Market restraint analysis
    3.4. Myasthenia Gravis Treatment Market Analysis Tools
    3.4.1. Industry Analysis - Porter’s
    3.4.1.1. Supplier power
    3.4.1.2. Buyer power
    3.4.1.3. Substitution threat
    3.4.1.4. Threat of new entrant
    3.4.1.5. Competitive rivalry
    3.4.2. PESTEL Analysis
    3.4.2.1. Political landscape
    3.4.2.2. Technological landscape
    3.4.2.3. Economic landscape
    Chapter 4. Myasthenia Gravis Treatment: Treatment Type Estimates & Trend Analysis
    4.1. Myasthenia Gravis Treatment Market: Key Takeaways
    4.2. Myasthenia Gravis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
    4.3. Cholinesterase Inhibitors
    4.3.1. Cholinesterase inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
    4.4. Chronic Immunomodulators
    4.4.1. Chronic immunomodulators market estimates and forecasts, 2018 to 2030 (USD Million)
    4.5. Monoclonal Antibodies
    4.5.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
    4.6. Rapid Immunotherapies
    4.6.1. Rapid immunotherapies market estimates and forecasts, 2018 to 2030 (USD Million)
    4.7. Thymectomy
    4.7.1. Thymectomy market estimates and forecasts, 2018 to 2030 (USD Million)
    4.8. Others
    4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
    Chapter 5. Myasthenia Gravis Treatment: End Use Estimates & Trend Analysis
    5.1. Myasthenia Gravis Treatment Market: Key Takeaways
    5.2. Myasthenia Gravis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
    5.3. Hospitals
    5.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
    5.4. Clinics
    5.4.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
    5.5. Others
    5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
    Chapter 6. Myasthenia Gravis Treatment Market: Regional Estimates & Trend Analysis
    6.1. Regional Outlook
    6.2. Myasthenia Gravis Treatment Market by Region: Key Marketplace Takeaway
    6.3. North America
    6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.3.2. U.S.
    6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.3.3. Canada
    6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.4. Europe
    6.4.1. UK
    6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.4.2. Germany
    6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.4.3. France
    6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.4.4. Italy
    6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.4.5. Spain
    6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.4.6. Sweden
    6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.4.7. Norway
    6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.4.8. Denmark
    6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.5. Asia Pacific
    6.5.1. Japan
    6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.5.2. China
    6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.5.3. India
    6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.5.4. Australia
    6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.5.5. Thailand
    6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.5.6. South Korea
    6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.6. Latin America
    6.6.1. Brazil
    6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.6.2. Mexico
    6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.6.3. Argentina
    6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.7. MEA
    6.7.1. Saudi Arabia
    6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.7.2. South Africa
    6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.7.3. UAE
    6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    6.7.4. Kuwait
    6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    Chapter 7. Competitive Landscape
    7.1. Recent Developments & Impact Analysis, By Key Market Participants
    7.2. Market Participant Categorization
    7.2.1. Alexion Pharmaceutical Inc.
    7.2.1.1. Company overview
    7.2.1.2. Financial performance
    7.2.1.3. Product benchmarking
    7.2.1.4. Strategic initiatives
    7.2.2. Grifols SA
    7.2.2.1. Company overview
    7.2.2.2. Financial performance
    7.2.2.3. Product benchmarking
    7.2.2.4. Strategic initiatives
    7.2.3. Avadel Pharmaceuticals, Plc.
    7.2.3.1. Company overview
    7.2.3.2. Financial performance
    7.2.3.3. Product benchmarking
    7.2.3.4. Strategic initiatives
    7.2.4. Novartis
    7.2.4.1. Company overview
    7.2.4.2. Financial performance
    7.2.4.3. Product benchmarking
    7.2.4.4. Strategic initiatives
    7.2.5. Pfizer, Inc.
    7.2.5.1. Company overview
    7.2.5.2. Financial performance
    7.2.5.3. Product benchmarking
    7.2.5.4. Strategic initiatives
    7.2.6. AbbVie Inc.
    7.2.6.1. Company overview
    7.2.6.2. Financial performance
    7.2.6.3. Product benchmarking
    7.2.6.4. Strategic initiatives
    7.2.7. F.Hoffmann-La Roche AG
    7.2.7.1. Company overview
    7.2.7.2. Financial performance
    7.2.7.3. Product benchmarking
    7.2.7.4. Strategic initiatives
    7.2.8. GlaxoSmithKline Plc.
    7.2.8.1. Company overview
    7.2.8.2. Financial performance
    7.2.8.3. Product benchmarking
    7.2.8.4. Strategic initiatives
    7.2.9. Bausch Health Companies Inc.
    7.2.9.1. Company overview
    7.2.9.2. Financial performance
    7.2.9.3. Product benchmarking
    7.2.9.4. Strategic initiatives
    7.2.10. Shire plc
    7.2.10.1. Company overview
    7.2.10.2. Financial performance
    7.2.10.3. Product benchmarking
    7.2.10.4. Strategic initiatives

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings